The objective of this study was to collect data on outcomes obtained when switching elderly nursing home residents with dementia from risperidone to quetiapine. Medical records were reviewed to identify dementia patients switched from risperidone to quetiapine. Clinical Global Impressions (CGI) scores assigned retrospectively (at switch and weeks 4-6) assessed treatment. Data from 15 men and 52 women (mean age, 82.8 years) were evaluated. The mean daily dose of risperidone at switch was 1.42 mg. Switching was abrupt in all but 2 patients. The mean daily dose of quetiapine after the switch was 87.3 mg. After the switch, the CGI Severity of Illness score remained unchanged, but the CGI Global Improvement score was positive. Fourteen patients reported somnolence; 3 patients discontinued quetiapine. Most patients in this study were switched from risperidone to quetiapine with no worsening of clinical status.
Madhusoodanan S, Brenner R, Gupta S, Bogunovic O.Quetiapine for elderly patients with psychosis. Clin Geriatrics. 2001;9:46-56.
2.
Henderson AS, Korten AE, Levings C, et al.Psychotic symptoms in the elderly: a prospective study in a population sample. Int J Geriatr Psychiatry. 1998;13:484-492.
3.
Devanand DP, Jacobs DM, Tang M-X, et al.The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997;54:257-263.
4.
Reisberg B, Franssen E, Sclan SG, Kluger A, Ferris SH.Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci. 1989;54:95-112.
5.
Tariot PN, Podgorski CA, Blazina L, Leibovici A.Mental disorders in the nursing home: another perspective. Am J Psychiatry. 1993;150:1063-1069.
6.
Madhusoodanan S, Bogunovic O.Safety of benzodiazepines in the geriatric population. Expert Opin Drug Saf. 2004;3:485-493.
7.
Svarstad BL, Mount JK, Bigelow W.Variations in the treatment culture of nursing homes and responses to regulations to reduce drug use. Psychiatr Serv. 2001;52:666-672.
8.
Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R.The use of atypical antipsychotics in nursing homes. J Clin Psychiatry. 2003;64:1106-1112.
9.
Masand PS.Side effects of antipsychotics in the elderly. J Clin Psychiatry. 2000;61(suppl 8):43-51.
10.
Jeste DV: Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(suppl 4):27-32.
11.
Caliguri MR, Jeste DV, Lacro JP.Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging. 2000;17:363-384.
12.
Madhusoodanan S, Brenner R.Update on risperidone use in elderly patients: a review. Clin Geriatrics. 2001;9: 32-43.
13.
Madhusoodanan S, Brenner R, Cohen CI.Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs. 1999;12:135-150.
14.
Wooltorton E: Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002; 167:1269-1270.
15.
Wooltorton E: Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ. 2004;170:1395-1395.
16.
Abilify [prescribing information]. New York, NY: Bristol Myers Squibb; 2005.
17.
FDA Safety Information and Adverse Event Reporting Program. 2003 safety alert—Risperdal (risperidone). Available at: www.fda.gov/medwatch/SAFETY/2003/risperdal.htm. Accessed December 3, 2004.
18.
DeVane CL, Mintzer J.Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update: Psychopharmacol Bull. 2003;37:116-132.
19.
European Agency for the Evaluation of Medicinal Products. EMEA public statement on the safety of olanzapine (Zyprexa, Zyprexa Velotab). Available at: www.emea.eu.int/pdfs/human/press/pus/085604en.pdf. Accessed December 3, 2004.
20.
Health Canada. Zyprexa (olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. Available at: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/zyprexa_hpc_e.html. Accessed December 3, 2004.
21.
Guy W.Clinical global impression. In: ECDEU Assessment Manual of Psychopharmacology (US Department of Health, Education, and Welfare publication D 76-338). Rockville, Md: National Institute of Mental Health; 1976:218-222.
22.
Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al.Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry. 1997;58:311-317.
23.
Madhusoodanan S, Suresh P, Brenner R, Pillai R.Experience with the atypical antipsychotics: risperidone and olanzapine in the elderly. Ann Clin Psychiatry. 1999;11:113-118.
24.
Banov MD, Zarate CA Jr, Tohen M, et al.Clozapine therapy in refractory affective disorders: polarity predicts response in long term follow up. J Clin Psychiatry. 1994;55:295-330.
25.
Pae CU, Lee KU, Kim JJ, et al.Switching to quetiapine in patients with acute mania who were intolerant to risperidone. Hum Psychopharmacol. 2004;19:47-51.
26.
Keller R, Mongini F.Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci. 2002;23:233-235.
27.
Kunwar AR, Megna JL.Resolution of risperidone-induced hyperprolactinemia with substitution of quetiapine. Ann Pharmacother. 2003;37:206-208.
28.
Takahashi H, Higuchi H, Kamata M, et al.Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsychiatry Clin Neurosci. 2003;15: 375-377.
29.
Takahashi H, Sugita T, Yoshida K, Higuchi H, Shimizu T.Effect of quetiapine in the treatment of panic attacks in patients with schizophrenia: 3 case reports. J Neuropsychiatry Clin Neurosci. 2004;16:113-115.
30.
Mullen J, Jibson MD, Sweitzer D.A comparison of the relative safety, efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther. 2001; 23:1839-1854.
31.
De Nayer A, Windhager E, Irmansyah X, et al, on behalf of the SPECTRUM Study Group. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics. Int J Psych Clin Pract. 2003;7:59-66.
32.
Madhusoodanan S, Brenner R, Alcantra A.Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol. 2000;13:28-32.
33.
McManus DQ, Arvanitis LA, Kowalcyk BB.Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry. 1999;60:292-298.
34.
Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW.Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther. 2000;22:1068-1084.
35.
Schneider L, Yeung P, Sweitezer DE, Arvantis L.Quetiapine may reduce hostility in patients with psychosis related to Alzheimer’s disease. Schizophr Res. 1999;36:295-296.
36.
Zhong K, Tariot P, Minkowitz MC, Devine NA, Mintzer J.Quetiapine for the treatment of agitation in elderly institutionalized patients with dementia: a randomized, double-blind trial. Poster presented at: 9th International Conference on Alzheimer’s Disease and Related Disorders; July 17-22, 2004; Philadelphia, Pa.
37.
Juncos JL, Roberts VJ, Evatt ML, et al.Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov Disord. 2004;19:29-35.
38.
Arvanitis LA, Miller BG.Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233-246.
